Hepatic Tumor Pipeline Analysis Report 2026

Report Coverage

The Hepatic Tumor Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hepatic tumor therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hepatic tumor. The hepatic tumor report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatic tumor pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatic tumor treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatic tumor.

Read more about this report - Request a Free Sample

Hepatic Tumor Pipeline Outlook

Hepatic tumor is a malignant growth in the liver, often arising from chronic liver diseases, viral infections such as hepatitis B or C, cirrhosis, or genetic mutations. Tumor cells proliferate uncontrollably, impairing liver function and potentially spreading to other organs. Early detection is essential for improved patient outcomes.

Hepatic tumor treatments include surgical resection, liver transplantation, targeted therapies, immunotherapy, and chemotherapy to control tumor growth, reduce metastasis, and enhance survival. For example, in May 2025, Galmed Pharmaceuticals’ Aramchol markedly boosted Bayer’s Regorafenib efficacy, significantly reducing hepatic tumor growth in preclinical models by enhancing autophagy and tumor cell death. A Phase 1b trial is scheduled for Q4 2025.

Hepatic Tumor Epidemiology

According to Walaa Abdelhamed et al., hepatocellular carcinoma (HCC), the most common malignant hepatic tumor, accounted for 906,000 new cases and 830,000 deaths globally in 2020. HCC represents approximately 90% of primary liver cancers. Patients with liver cirrhosis, particularly those with hepatitis B or C infections, show significantly higher incidence, with yearly and five-year cumulative rates of 1%-4% and 5%-30%, respectively. Hepatitis B remains the leading risk factor, causing nearly 50% of cases. The ongoing advancements in the HCC drug pipeline aim to improve survival outcomes and provide targeted, effective therapies for high-risk patient populations.

Hepatic Tumor – Pipeline Therapeutic Assessment

Hepatic Tumor Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 51%, covers a major share of the total hepatic tumor clinical trials. It is followed by phase I at 30%, and phase III at 13%. This distribution indicates a strong focus on drug development and optimization, with substantial investments in early and mid-stage trials. Such segmentation enhances the likelihood of introducing effective therapies to the market, potentially improving patient outcomes and advancing treatment options for hepatic tumors.

Hepatic Tumor Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hepatic tumor pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hepatic tumor report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatic tumors. Immune checkpoint inhibitors are emerging as a promising drug class in the hepatic tumor pipeline. For example, Henlius’ HLX13, an anti-CTLA-4 fully human monoclonal antibody biosimilar of ipilimumab, entered a Phase 1/3 clinical trial in May 2025. HLX13 is being evaluated for unresectable advanced hepatocellular carcinoma in combination with nivolumab, aiming to enhance T-cell-mediated tumor cell death and improve patient outcomes.

Hepatic Tumor Clinical Trials – Key Players

The EMR report for the hepatic tumor pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatic tumor therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatic tumor clinical trials:

• Tempest Therapeutics
• TriSalus Life Sciences, Inc.
• Captor Therapeutics S.A.
• Qilu Pharmaceutical Co., Ltd.
• Shanghai Henlius Biotech
• Tvardi Therapeutics, Incorporated
• Hoffmann-La Roche
• METiS Pharmaceuticals
• Etnova Therapeutics Corp.
• Chugai Pharmaceutical
• Tyra Biosciences, Inc.
• Chiome Bioscience Inc.
• SEED Therapeutics, Inc.

Hepatic Tumor – Emerging Drugs Profile

Key Questions Answered in the Hepatic Tumor Pipeline Insight Report

• Which companies/institutions are leading the hepatic tumor drug development?
• Which company is leading the hepatic tumor pipeline development activities?
• What is the current hepatic tumor commercial assessment?
• What are the opportunities and challenges present in the hepatic tumor pipeline landscape?
• What is the efficacy and safety profile of hepatic tumor pipeline drugs?
• Which company is conducting major trials for hepatic tumor drugs?
• Which companies/institutions are involved in hepatic tumor collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hepatic tumor?

Reasons To Buy This Report

The Hepatic Tumor Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hepatic tumor. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatic tumor collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Cancer Tumor Profiling Market

Tumor Ablation Market Report